Association of CD49d and CD44 in CLL Patients and Their Role in Prognosis
研究概览
详细说明
Chronic lymphocytic leukemia (CLL) is the most common type of chronic leukemia, accounting for approximately 40% of all leukemia's and mainly affecting older individuals. As it has a highly variable clinical course, identification of molecular and biological prognostic markers has provided new insights into the risk stratification of patients with CLL .
The interactions of chronic lymphocytic leukemia cells with the microenvironment in secondary lymphoid tissues and the bone marrow are known to promote CLL cell survival and proliferation . CD49d (one of biomarkers) is one of independent prognostic risk parameter in CLL with important roles in shaping these interactions.
CD49d also is one of independent prognostic risk parameters in CLL that predict adverse outcome and linked to processes involved in interaction with the vascular endothelium and/or migration into the extravascular compartments .
The cell-surface glycoprotein CD44 is involved in cell motility, cellular trafficking, and stem cell differentiation . It contributes to the phenotypic hallmarks of many cancers, such as invasiveness, self-renewal, and sustained survival. CD44 transmits both growth and apoptotic signals, a functional duality that is also observed in hematologic malignancies.
CD44 expression in CLL is mediated by the tumor microenvironment. As a coreceptor, CD44 promotes leukemogenesis by regulating stimuli of MCL1 expression. Moreover, CD44 can be addressed therapeutically in CLL by specific antibodies.
研究类型
注册 (预期的)
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
取样方法
研究人群
30 patients All patients are newly diagnosed as CLL patients with associated malignancies
- Clinical history and clinical examination by the physician.
- Complete blood picture: on peripheral blood sample.
- BM aspiration: allowing diagnosis of the type of leukemia.
- Immunophenotyping by flowcytometer: will be done on peripheral blood or bone marrow aspirate specimens for establishing diagnosis of CLL by detecting its markers ( CD5,CD19,CD23) and for detecting membrane expression of CD49d and CD 44
描述
Inclusion Criteria:
- All patients are newly diagnosed as CLL
Exclusion Criteria:
- : patients with associated malignancies
学习计划
研究是如何设计的？
设计细节
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To what extent the identification of molecular and biological prognostic markers has provided new insights into the risk stratification of patients with CLL .
大体时间：1 YEAR
|
detecting membrane expression of CD49d and CD 44 and thier role in prognosis of CLL patients.
|
1 YEAR
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.